A Phase 1 Study of the IRAK4 inhibitor, AZD6793, evaluating Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Patients with COPD

Authors
Category Primary study
ConferenceEuropean respiratory journal
Year 2025
This article has no abstract
Epistemonikos ID: c846f23659e7ff2116c9323c4199aa51e764b869
First added on: Apr 18, 2026